Literature DB >> 23374051

Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort.

K Danielsen1, A O Olsen, T Wilsgaard, A-S Furberg.   

Abstract

BACKGROUND: There is indication of an increasing prevalence of psoriasis in some western populations. However, the results are not conclusive.
OBJECTIVES: To analyse trends in the prevalence of psoriasis over the past 30 years, separating age, birth cohort and time period effects.
METHODS: Five population-based surveys in North Norway, the Tromsø Studies 2-6, collected between 1979 and 2008, were studied. Participants aged 20-79 years with self-reported psoriasis data in at least one of the surveys were included, yielding a total of 69,539 observations from 33,387 unique individuals born between 1915 and 1977. Trends in psoriasis prevalence were examined using cross-sectional, time lag and longitudinal designs of graphical plots. Observed trends were further evaluated in generalized linear-regression models.
RESULTS: The self-reported lifetime prevalence of psoriasis increased from 4·8% in 1979-1980 to 11·4% in 2007-2008. Graphical plots showed an increasing prevalence of psoriasis with each consecutive survey in all examined age groups and birth cohorts, leaving time period effects as the explanation for the increase. The odds for psoriasis in the cohort were 2·5 times higher in 2007-2008 than in 1979-1980 (adjusted odds ratio 2·49, 95% confidence interval 2·08-2·99). The prevalence of persons reporting a doctor's diagnosis of psoriasis was 9·9% in the last survey. In subgroups of the study population, psoriasis was associated with higher body mass index, lower physical activity during work and leisure time, lower educational level and smoking.
CONCLUSIONS: Our findings indicate an increasing prevalence of self-reported psoriasis. This could represent a true increase in prevalence, possibly due to changes in lifestyle and environmental factors, or an increased awareness of the disease.
© 2013 The Authors. BJD © 2013 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2013        PMID: 23374051     DOI: 10.1111/bjd.12230

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  56 in total

1.  Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis.

Authors:  Gaku Tsuji; Akiko Hashimoto-Hachiya; Vu Hai Yen; Masaki Takemura; Ayako Yumine; Kazuhisa Furue; Masutaka Furue; Takeshi Nakahara
Journal:  Cell Death Discov       Date:  2020-03-04

2.  Psoriasis and Sleep Apnea: A Danish Nationwide Cohort Study.

Authors:  Alexander Egeberg; Usman Khalid; Gunnar Hilmar Gislason; Lotus Mallbris; Lone Skov; Peter Riis Hansen
Journal:  J Clin Sleep Med       Date:  2016-05-15       Impact factor: 4.062

3.  The Association Between Forkhead Box Class O3A Gene Polymorphism and Psoriasis and Its Relationship with Psoriasis Severity.

Authors:  Ahmed Ibrahim Abd Elneam; Ghadah Alhetheli; Mohammed Saleh Al-Dhubaibi; Ali Ismaeil Ali Abd Alrheam; Ahmed El-Sayed Hassan
Journal:  J Clin Aesthet Dermatol       Date:  2022-08

4.  Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.

Authors:  Lazaro E Aira; Alejandro López-Requena; Dasha Fuentes; Liset Sánchez; Teresita Pérez; Aleida Urquiza; Heber Bautista; Leopoldina Falcón; Patricia Hernández; Zaima Mazorra
Journal:  MAbs       Date:  2014-03-04       Impact factor: 5.857

5.  Echocardiographic and electrocardiographic assessments in patients with psoriasis.

Authors:  Zeinab Aryanian; Iraj Jafaripour; Edris Kohneshin; Roghayeh Pourkia; Mohammad Taghi Hedayati Goudarzi; Soudabeh Tirgar Tabari; Azar Shirzadian Kebria; Farbod Zahedi Tajrishi; Mohammad Mostafa Ansari Ramandi
Journal:  Caspian J Intern Med       Date:  2021-03

6.  Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis.

Authors:  Qian Zou; Jiawei Si; Yatao Guo; Jiayu Yu; Huijuan Shi
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

7.  Seasonal Variation of Psoriasis and Its Impact in the Therapeutic Management: A Retrospective Study on Chinese Patients.

Authors:  Xuanwei Zheng; Qiaolin Wang; Yan Luo; Wenhua Lu; Liping Jin; Menglin Chen; Wu Zhu; Yehong Kuang
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-05-10

8.  A Correlative Study between Platelet Count, Mean Platelet Volume and Red Cell Distribution Width with the Disease Severity Index in Psoriasis Patients.

Authors:  Vijayashree Raghavan; Rajesh Kanna Nandagopal Radha; Ramesh K Rao; Abinaya Kuberan
Journal:  J Clin Diagn Res       Date:  2017-09-01

9.  Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.

Authors:  R B Warren; M Lebwohl; H Sofen; V Piguet; M Augustin; F Brock; F Fierens; A Blauvelt
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-08-17       Impact factor: 9.228

10.  Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.

Authors:  A Blauvelt; C Paul; P van de Kerkhof; R B Warren; A B Gottlieb; R G Langley; F Brock; C Arendt; M Boehnlein; M Lebwohl; K Reich
Journal:  Br J Dermatol       Date:  2020-09-06       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.